Andrea Angelini
University of Padua
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrea Angelini.
Journal of Surgical Oncology | 2012
Andrea Angelini; Giovanni Guerra; Andreas F. Mavrogenis; Elisa Pala; Piero Picci; Pietro Ruggieri
Aim of this study was to analyze (1) survival, local recurrence (LR), and metastasis rates between the three histological tumor grades; (2) whether type of treatment and tumor site influenced prognosis for each histologic grade.
Journal of Surgical Oncology | 2013
Elisa Pala; Eric R. Henderson; Teresa Calabrò; Andrea Angelini; Cn Abati; Giulia Trovarelli; Pietro Ruggieri
Retrospectively analyze outcomes of current‐generation Global Modular Replacement System (GMRS) modular tumor endoprosthesis for the lower limb in primary and secondary implantation procedures.
Injury-international Journal of The Care of The Injured | 2010
Pietro Ruggieri; Andreas F. Mavrogenis; Roberto Casadei; Costantino Errani; Andrea Angelini; Teresa Calabrò; Elisa Pala; Mario Mercuri
Long bone pathological fractures in patients with primary and metastatic bone tumours are difficult to treat and their management may alter the prognosis of the disease and jeopardize survival. The aim of this article was to review the relevant studies reporting on the management of tumour patients with pathological fractures of the long bones, to discuss the most suitable approach in these patients, to highlight specific treatment recommendations, and finally based on this analysis and our clinical practice, to propose a treatment algorithm for decision making and treatment.
Spine | 2012
Pietro Ruggieri; Andrea Angelini; Elisa Pala; Mario Mercuri
Study Design. Retrospective case series. Objective. To evaluate the risk of infection, related treatment, and outcome after surgery of the 2 most common primary sacral tumors. Summary of Background Data. Rarity of sacral tumors has limited the number of population-based studies. Treatment depends on malignancy or local aggressiveness: wide resection is indicated for malignant lesions, intralesional surgery for benign. Methods. We studied 82 patients with sacral chordomas (55 cases) or giant cell tumor (GCT) (27 cases) treated between 1976 and 2005. All patients had IV antibiotic therapy with amikacin and teicoplanin. Surgery of chordoma was resection; surgery of GCT was intralesional excision. Infections were classified as immediate postoperative, early (within 6 months), and late (more than 6 months from surgery). Mean follow-up was 9.5 years (range: 3–27 years). Some factors possibly influencing the risk of infection were statistically analyzed by Kaplan Meier curves and log-rank test. Results. No deep infections were observed in the GCT series. Three patients with sacral chordoma died for postoperative complications and were excluded from this analysis. Of the remaining 52 patients with chordoma, 23/52 had deep wound infection (44%) that required 1 or more surgical debridements combined with antibiotics, according to cultures. In 16 patients (70%), infection occurred within 4 weeks postoperatively, and in 7 within 6 months. Most frequent bacteria were Enterococcus (23%), Escherichia coli (20%), and Pseudomonas aeruginosa (18%). In 74% of cases, infection was multimicrobial. Level of resection, previous intralesional treatment elsewhere, tumor volume, and age did not statistically influence risk of infection. Conclusion. Type of surgery was the prominent factor related to a major risk of infection. Operating procedure time correlated as well. Resections of sacral chordoma imply a high risk of deep infection, while intralesional excision of GCT does not. All infections healed with surgical debridements and antibiotic therapy.
Skeletal Radiology | 2011
Pietro Ruggieri; Maurizio Montalti; Andrea Angelini; Marco Alberghini; Mario Mercuri
Gorham–Stout disease (also known as “disappearing bone disease”) was first described by Jackson in 1838, but was properly defined by Gorham and Stout in a series of 24 patients in 1954–1955. It is a rare disease of unknown etiology (about 200 cases reported in the literature) characterized by spontaneous progressive resorption of bone without malignant proliferation of vascular structures. The diagnosis is one of exclusion and it is based on combined histological, radiological, and clinical features. Benign vascular proliferation with fatty bone marrow and thinning of bony trabeculae is a typical histological feature. Standard radiographs of disappearing bone disease show progressive bony resorption with adjacent soft tissue involvement. Most cases of Gorham–Stout disease resolve spontaneously, but prognosis remains unpredictable. This study reports 13 cases of Gorham–Stout disease treated in our institution from 1968 to 2008. The aim of the work was to review our series and the literature on this rare disease, as well as to evaluate whether or not an optimal treatment can be identified and recommended.
Journal of Surgical Oncology | 2015
Andrea Angelini; Elisa Pala; Teresa Calabrò; Marco Maraldi; Pietro Ruggieri
The best treatment of sacral chordoma is surgical resection, nowadays associated with optimized radiation therapy. We analysed 1) the oncologic outcome in a large series; 2) the effect of previous intralesional surgery, resection level, tumor volume and margins on survivorship to local recurrence (LR) and 3) the complication rate.
Journal of Surgical Oncology | 2013
Andreas F. Mavrogenis; Elisa Pala; Andrea Angelini; A. Ferraro; Pietro Ruggieri
Previous studies reported variable outcome of proximal tibial resections and reconstructions. Therefore, we evaluated the survival, Musculoskeletal Tumor Society (MSTS) function, and complications of patients and reconstructions in this location.
The Clinical Journal of Pain | 2016
Andreas F. Mavrogenis; Andrea Angelini; Christos Vottis; Elisa Pala; Teresa Calabrò; Panayiotis J. Papagelopoulos; Pietro Ruggieri
Background:Metastatic disease is the most common malignancy of the bone. Prostate, breast, lung, kidney, and thyroid cancer account for 80% of skeletal metastases. Bone metastases are associated with significant skeletal morbidity including severe bone pain, pathologic fractures, spinal cord or nerve roots compression, and malignant hypercalcemia. These events compromise greatly the quality of life of the patients. The treatment of cancer patients with bone metastases is mostly aimed at palliation. Objective:This article aims to present these palliative treatments for the patients with bone metastases, summarize the clinical applications, and review the techniques and results. Methods:It gives an extensive overview of the possibilities of palliation in patients with metastatic cancer to the bone. Results and Discussion:Currently, modern treatments are available for the palliative management of patients with metastatic bone disease. These include modern radiation therapy, chemotherapy, embolization, electrochemotherapy, radiofrequency ablation, and high-intensity focused ultrasound. As such it is of interest for all physicians with no experience with these developments to make palliative procedures safer and more reliable.
Spine | 2013
Andrea Angelini; Pietro Ruggieri
Study Design. Operative technique. Objective. To report a new technique for sacral resection, with short-term preliminary results. Summary of Background Data. Although various reports analyzed en bloc excision of sacral tumors, there are still technical problems to improve protection of nerve roots, preserve surrounding structures, and reduce intraoperative bleeding, while maintaining the oncological result. Methods. Thirteen patients were resected for their sacrococcygeal tumor by following the described technique. Two patients had undergone previous surgery elsewhere. The sacrum was exposed by a posterior midline incision and complete soft-tissue dissection. Lateral osteotomies were performed through the sacral foramina using a threadwire saw (devised by Tomita and Kawahara) and Kerrison rongeurs, to avoid damage to the sacral roots. After proximal osteotomy, the sacrum was laterally elevated and mobilized to allow dissection of presacral structures. Mean surgical time was 5.5 hours (range; 1.5–8). Mean blood loss was 2961 mL (range; 1000–8000 mL). Results. Level of resection was proximal in 9 patients and at S3 or below in 4. Margins were wide in 10 patients, marginal in 1, and intralesional in 2. At a mean follow-up of 35.5 months, 9 patients were disease free, while the tumor recurred locally in 4 cases. Complications requiring surgery were seen in 1 case. Conclusion. The reported technique allows wide margins with preservation of roots, and reduction in blood loss and operative time. Indications for posterior-only approach can be extended to resection proximal to S3, when there is minimal pelvic invasion and none or partial involvement of sacroiliac joints. However, the long-term benefits of this technique need to be evaluated.
Surgical Infections | 2015
Andreas F. Mavrogenis; Elisa Pala; Andrea Angelini; Teresa Calabrò; Carlo Romagnoli; Matteo Romantini; Gabriele Drago; Pietro Ruggieri
BACKGROUND Infection of megaprostheses after bone tumor resection is a major concern; management is challenging. This study evaluated the survivability from such infections, the microbial isolates, treatment tactics, and outcome of megaprosthesis reconstructions. MATERIALS AND METHODS We studied 1,161 patients retrospectively who underwent megaprosthesis reconstruction for limb salvage after a sarcoma from 1983 to 2010. The mean followup was 9 y (range 3-20 y). We evaluated the overall survival of the megaprosthesis reconstructions in patients with infection and the survival with respect to the type of megaprosthesis, site of reconstruction, cemented or cementless fixation, type of tumor, adjuvant treatments, microbial isolate(s), treatment tactics, and outcome. RESULTS The incidence of infection was 8.6%. The most common microbial isolate was Staphylococcus epidermidis (47%). Overall survival with definitive management of infection was 88% at 10 y and 84% at 20 y. Survival was higher for cementless reconstructions and not different with respect to the type of megaprosthesis, site of reconstruction, or adjuvant therapy. Infections resolved completely with one- or two-stage surgery in 75% of patients. The rate of amputation because of infection was 21%. CONCLUSIONS Megaprosthesis reconstructions may be infected in 8.6% of cases. Infections more commonly occur late, caused usually by S. epidermidis. The survival rate is higher with cementless megaprosthesis reconstructions and no different with respect to the type of tumor or megaprosthesis or the adjuvant treatments. One-stage revision is effective for acute post-operative infections; however, two-stage revision surgery is necessary for early and late infections. The rate of amputation because of occurrence or persistence of megaprosthesis infection is 21%.